74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Pacific Biosciences of California Inc
Closed
SectorHealthcare
1.13 -2.59
Overview
Share price change
24h
Min
1.13
Max
1.18
Income | 63M 2.4M |
|---|---|
Sales | -743K 39M |
EPS | -0.2 |
Profit margin | 6.045 |
Employees | 575 |
EBITDA | -123M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +79.49% upside |
Next Earnings | 8 May 2025 |
|---|
Market Cap | 340M |
|---|---|
Previous open | 3.72 |
Previous close | 1.13 |
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Pacific Biosciences of California Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Pacific Biosciences of California Inc Forecast
Price Target
By TipRanks
79.49% upside
12 Months Forecast
Average 2.1 USD 79.49%
High 3 USD
Low 1.5 USD
Based on 10 Wall Street analysts offering 12 month price targets forPacific Biosciences of California Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Pacific Biosciences of California Inc
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
